Biovet, part of the Bharat Biotech Group, has received approval from the Central Drugs Standard Control Organisation (CDSCO) for its Lumpy Skin Disease (LSD) vaccine, BIOLUMPIVAXIN, designed for dairy cattle and buffaloes.
This vaccine, the only one of its kind globally for LSD, is both safe and effective. It also has a unique ability to differentiate between naturally infected animals and those that have been vaccinated.
Tested rigorously for quality, safety, and effectiveness at ICAR-NRCE and the Indian Veterinary Research Institute (IVRI), the vaccine promises to be a breakthrough in veterinary medicine.
Dr. Krishna Ella, Founder of Biovet, described the DIVA marker vaccine as a game-changer, stating, “Veterinarians and epidemiologists can now easily distinguish between animals vaccinated with BIOLUMPIVAXIN® and those previously infected with LSD.”
He added that the CDSCO approval marks a significant step toward India’s self-reliance in veterinary healthcare, reducing the need for imported vaccines and aiding India’s progress toward a disease-free livestock population.
The Development
This live-attenuated marker vaccine was developed using the LSD virus strain from Ranchi/2019 by ICAR-NRCE in collaboration with Biovet. The development, spanning three years, was spearheaded by NRCE scientists under the leadership of Dr. Naveen Kumar and Dr. B. N. Tripathi, with crucial contributions from ICAR in creating this world-class vaccine for animal health.
